Skip to main content
CTOS 2024 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Sarcoma of the Year: Dedifferentiated Liposarcoma

Friday, November 15, 2024
9:00 AM – 10:00 AM PST
Location: Harbor Ballroom

Presentations:

  • 9:00 AM – 10:00 AM PST
    BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

    Author: Patrick Schöffski, Prof Dr – Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven

    Co-Author: Roberta Sanfilippo, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

    Co-Author: Javier Martin-Broto, MD, PhD – Fundación Jiménez Díaz University Hospital

    Co-Author: Akira Kawai, MD – National Cancer Center Hospital Japan

    Co-Author: Jayesh Desai, MBBS, FRACP – Royal Melbourne Hospital and Peter MacCallum Cancer Centre

    Co-Author: Patricia LoRusso, DO, PhD(H) – Yale University School of Medicine, Yale Cancer Center

    Co-Author: Robert G. Maki, MD, PhD (he/him/his) – Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College

    Co-Author: Robin L. Jones, BSc, MB BS, MRCP, MD – Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

    Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon Bérard

    Co-Author: Alannah Smrke, MD, FRCPC – BC Canada

    Co-Author: Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI – Toronto Sarcoma Program, Princess Margaret Cancer Center

    Co-Author: Antoine Italiano, MD, PhD – Institut Bergonié

    Co-Author: Ana Sebio, MD, PhD – Hospital de la Santa Creu i Sant Pau

    Co-Author: Rastislav Bahleda, MD – Institut Gustave Roussy

    Co-Author: Yeh Chen Lee, MD (she/her/hers) – Prince of Wales Hospital

    Co-Author: Winette van der Graaf, MD, PhD – Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center

    Co-Author: Xing Zhang, MD, PHD – Sun Yat-Sen University Cancer Center

    Co-Author: Medhi Lahmar, MD, PhD – Boehringer Ingelheim International GmbH

    Co-Author: Michael Teufel, PhD (he/him/his) – Boehringer Ingelheim Pharmaceuticals Inc.

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

  • 9:00 AM – 10:00 AM PST
    COMBINATION OF MDM2 AND CDK4/6 INHIIBITOR IN PATIENTS WITH ADVANCED WELL AND DE-DIFFERENCIATED LIPOSARCOMA AND OTHERS CANCERS: COHORT ANALYSIS FROM THE MEGAMOST PHASE II BASKET STUDY

    Author: Armelle Dufresne, MD PhD – Centre Leon Berard

    Co-Author: Carlos Gomez-Roca, MD – Oncopole de Toulouse

    Co-Author: Cecile Dalban, Mrs – Centre Leon Berard

    Co-Author: Antoine Italiano, MD, PhD – Institut Bergonié

    Co-Author: Esma Saada-Bouzid, MD – Centre Lacassagne

    Co-Author: Francois Bertucci, MD – Institut Paoli Calmettes

    Co-Author: Axel Le Cesne, MD – Gustave Roussy

    Co-Author: Olivier Tredan, MD PhD – Centre Leon Berard

    Co-Author: Philippe Cassier, MD PhD – Centre Leon Berard

    Co-Author: Anne Sophie Bidaux, Mrs – Centre Leon Berard

    Co-Author: Delphine Tatu, Mrs – Centre Leon Berard

    Co-Author: Mathilde Bernardin, Mrs – Centre Leon Berard

    Co-Author: Moly Long, Mrs – Centre Leon Berard

    Co-Author: David Perol, PhD – Centre Leon Berard

    Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon Bérard

    Co-Author: Mehdi Brahmi, MD, PhD – Centre Leon Berard

  • 9:00 AM – 10:00 AM PST
    A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

    Author: Evan Rosenbaum, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Li-Xuan Qin, PhD – Memorial Sloan Kettering Cancer Center

    Co-Author: Rodrigo Gularte Mérida, Ph. D. – Memorial Sloan Kettering Cancer Center

    Co-Author: Evan Seffar, MS – Memorial Sloan Kettering Cancer Center

    Co-Author: Mark Dickson, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Sujana Movva, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Ciara Kelly, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Viswatej Avutu, MD (he/him/his) – Memorial Sloan Kettering Cancer Center

    Co-Author: Jason Chan, MD, PhD – Memorial Sloan Kettering Cancer Center

    Co-Author: Ping Chi, MD, PhD – Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine

    Co-Author: Lauren Banks, MD, PhD (she/her/hers) – Memorial Sloan Kettering Cancer Center

    Co-Author: Mary Lou Keohan, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Mrinal Gounder, MD – Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College

    Co-Author: Robert G. Maki, MD, PhD (he/him/his) – Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College

    Co-Author: Damon Reed, MD – Memorial Sloan Kettering

    Co-Author: Jae Cho, n/a – Memorial Sloan Kettering Cancer Center

    Co-Author: Matthew Biniakewitz, RN – Memorial Sloan Kettering Cancer Center

    Co-Author: Rhoena Desir, n/a – Memorial Sloan Kettering Cancer Center

    Co-Author: Joseph Erinjeri, MD, PhD – Memorial Sloan Kettering Cancer Center

    Co-Author: Robert Lefkowitz, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Andrew Koff, Ph. D. – Memorial Sloan Kettering Cancer Center

    Co-Author: Samuel Singer, MD, FACS – Memorial Sloan Kettering Cancer Center

    Co-Author: William D. Tap, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College

    Co-Author: Sandra P. D'Angelo, MD – Memorial Sloan Kettering Cancer Center

  • 9:00 AM – 10:00 AM PST
    SINGLE CELL ATLAS OF WELL DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA SUGGESTS UNDERLYING EPIGENETIC PROGRAMS DRIVING TRANSTION BETWEEN WELL- AND DE-DIFFERENTIATED STATES

    Co-Author: Veena Kochat, PhD – MD Anderson Cancer Center

    Co-Author: Emre Arslan, PhD – MD Anderson Cancer Center

    Author: Ryan A. Denu, MD, PhD (he/him/his) – MD Anderson Cancer Center

    Co-Author: Danh D. Truong, PhD (he/him/his) – MD Anderson Cancer Center

    Co-Author: Corey Weistuch, PhD (he/him/his) – Memorial Sloan Kettering Cancer Center

    Co-Author: Margarita Divenko, n/a – Baylor College of Medicine

    Co-Author: Manrong Wu, n/a – The University of Texas MD Anderson Cancer Center

    Co-Author: William Padron, n/a – The University of Texas MD Anderson Cancer Center

    Co-Author: Davis Ingram, n/a – MD Anderson Cancer Center

    Co-Author: Khalida Wani, PhD – The University of Texas MD Anderson Cancer Center

    Co-Author: Christina Roland, MD, MS (she/her/hers) – The University of Texas MD Anderson Cancer Center

    Co-Author: Emily Keung, MD – MD Anderson Cancer Center

    Co-Author: Elise Nassif Haddad, MD – The University of Texas MD Anderson Cancer Center

    Co-Author: Alexander Lazar, MD PhD – MD Anderson Cancer Center

    Co-Author: Joseph Ludwig, MD – MD Anderson Cancer Center

    Co-Author: Neeta Somaiah, MD – The University of Texas MD Anderson Cancer Center

    Co-Author: Kunal Rai, PhD – MD Anderson Cancer Center

  • 9:00 AM – 10:00 AM PST
    TARGETING DEDIFFERENTIATED LIPOSARCOMA CELL OF ORIGIN WITH TGF-BETA INHIBITION

    Author: Sarah Watson, MD, PhD – Curie

    Co-Author: Nadège Gruel, PhD – Institut Curie

    Co-Author: Bastien Manciot, MSc – Institut Curie

    Co-Author: Laetitia Lesage, n/a – Institut Curie

    Co-Author: Chloé Quignot, PhD – Institut Curie

    Co-Author: Dimitrios Tzanis, MD, PhD – Institut Curie

    Co-Author: Sylvie Bonvalot, MD – Institut Curie

    Co-Author: Sophie El Zein, MD – Institut Curie

    Co-Author: Didier Decaudin, MD,PhD – Institut Curie

    Co-Author: Laetitia Linares, PhD – CRCM

    Co-Author: Olivier Delattre, MD, PhD – Institut Curie

    Co-Author: Joshua Waterfall, PhD – Institut Curie

    Co-Author: Gaelle Pierron, PhD – Institut Curie